drugset / Trial / NCT06269705

ZILRETTA in Subjects With Shoulder Osteoarthritis

NCT06269705

Phase 3 Active not recruiting 150 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupSingle-blindTreatment

Summary

Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, and normal saline placebo * To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline placebo

Timeline

Start
2024-02-05
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 32 mg Other

Indications